“…The Italian study has, however, demonstrated that patients who received the treatment had no new MRI-detectable lesions (this composite is routinely used for the assessment of the pharmacological agent used in the treatment of MS). This effect was not statistically significant but could have reached the level of p < 0.05 if more patents had been recruited [22,23]. This effect, however, was seen only in a subgroup of patients.…”